WOBURN, Mass.--(BUSINESS WIRE)--An abstract from Quad Technologies (”Quad”) has been accepted for presentation at the 58th annual American Society of Hematology meeting in San Diego, CA on December 3-6, 2016. The abstract is published on the ASH website at http://www.hematology.org/.
In collaboration with an external partner focused on CAR-T cancer immunotherapy, the focus of the poster presentation is the use of a phase change hydrogel substrate to activate and expand T cells and its subsequent influence on CD8+ cells expressing central memory and naïve phenotypic markers. The research outcome presents a T cell activation and expansion methodology that provides novel bioprocessing solutions to address cell therapy manufacturing challenges associated with magnetic de-beading and other workflow inefficiencies present today.
Andrew Ball, Ph.D leader of the study and Vice President of R&D at Quad notes, “We are excited that this abstract was accepted and will be presented at ASH 2016. The work highlights the use of a differentiated approach to activate, expand and preferentially modulate phenotypic marker expression in T lymphocytes. We look forward to advancing this research in areas that can best support clinical cell therapy manufacturing workflows.”
Title: Novel Phase-Change Hydrogel Substrate for T Cell Activation
Promotes Increased Expansion of CD8+ Cells Expressing Central Memory and
Naive Phenotype Markers (Abstract #3368)
Session Name: 711. Cell Collection and Processing: Poster II
Session Date: Sunday, December 4, 2016
Session Time: 6:00 PM-8:00 PM (San Diego Convention Center Hall GH)
About Quad Technologies
Quad Technologies is a developer of a differentiated dissolvable hydrogel used for cell separation and expansion in research and clinical applications. With a customer-centric product driven business model, the company is committed to addressing the needs of researchers and clinical bioprocess developers working in cell based therapeutics. www.quadtechnologies.com